<DOC>
	<DOCNO>NCT00423085</DOCNO>
	<brief_summary>The purpose study investigate 5cm^2 10cm^2 dos rivastigmine transdermal patch term efficacy safety patient probable Alzheimer 's Disease ( MMSE [ Mini Mental State Examination ] 10-20 ) . A 52-week extension phase evaluate safety tolerability long-term treatment rivastigmine transdermal patch patient probable Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Efficacy Safety Rivastigmine Transdermal Patch Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Patients randomly assign double-blind manner one 3 treatment arm ( placebo , rivastigmine 5 cm^2 rivastigmine 10 cm^2 ) ratio 1:1:1 . During Double-blind treatment phase , patient enter 16-week Titration Period follow 8-week Maintenance Period . During open-label extension phase , patient start treatment 2.5 cm^2 patch dose increase 10 cm^2 16-week titration period , follow maintenance period 36 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>A diagnosis dementia Alzheimer 's type accord DSMIV criterion A clinical diagnosis probable AD accord NINCDS/ADRDA criterion An MMSE score &gt; = 10 &lt; = 20 A current DSMIV diagnosis major depression Taken rivastigmine past A score &gt; 5 Modified Hachinski Ischemic Scale ( MHIS ) Other protocoldefined inclusion/exclusion criterion may apply Other protocoldefined inclusion/exclusion criterion may apply Extension Phase Eligibility Criteria Patients complete Doubleblind Treatment Phase study medication Exclusion Criteria Patients important protocol deviation completion Doubleblind Treatment Phase</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>rivastigmineï¼ŒAlzheimer 's Disease , transdermal patch</keyword>
</DOC>